Alfonso Segarra
Overview
Explore the profile of Alfonso Segarra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
185
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goicoechea M, Alvarez V, Segarra A, Polaina M, Martin-Reyes G, Robles N, et al.
Nefrologia (Engl Ed)
. 2022 Oct;
42(3):301-310.
PMID: 36210619
Background And Objective: To describe the clinical characteristics, the reasons for initiating therapy and the effects of treatment in the initial phase of evolocumab availability in the Nephrology Units of...
2.
Goicoechea M, Alvarez V, Segarra A, Polaina M, Martin-Reyes G, Robles N, et al.
Nefrologia (Engl Ed)
. 2021 Aug;
PMID: 34389184
Background And Objective: To describe the clinical characteristics, the reasons for initiating therapy and the effects of treatment in the initial phase of evolocumab availability in the Nephrology Units of...
3.
Fernandez-Juarez G, Rojas-Rivera J, Logt A, Justino J, Sevillano A, Caravaca-Fontan F, et al.
Kidney Int
. 2020 Nov;
99(4):986-998.
PMID: 33166580
A cyclical corticosteroid-cyclophosphamide regimen is recommended for patients with primary membranous nephropathy at high risk of progression. We hypothesized that sequential therapy with tacrolimus and rituximab is superior to cyclical...
4.
Segarra A, Martinez C, Carnicer C, Perich C, Jatem E, Martin M
Clin Lab
. 2019 Nov;
65(11).
PMID: 31710440
Background: Urinary levels of epidermal growth factor to creatinine ratio are considered as an early predictor of interstitial kidney fibrosis but so far no data are available on their biological...
5.
Segarra A, Carnicer C, Jatem E, Martin M, Molina M, Perich C, et al.
Clin Lab
. 2019 Jun;
65(6).
PMID: 31232037
Background: Urinary levels of EGF may be a noninvasive biomarker of the degree of interstitial fibrosis. However, all the available data are based on studies that examined the EGF/creatinine ratio...
6.
Cases A, Portoles J, Calls J, Martinez-Castelao A, Munar M, Segarra A
Int Urol Nephrol
. 2014 Aug;
46(10):1983-95.
PMID: 25118611
Purpose: To assess whether the correction dose recommended by the summary of product characteristics was adequate and to confirm the adequacy of the recommended conversion dosing strategies from shorter-acting erythropoiesis-stimulating...
7.
Segarra A, de la Torre J, Ramos N, Quiroz A, Garjau M, Torres I, et al.
Clin J Am Soc Nephrol
. 2011 Aug;
6(10):2411-20.
PMID: 21852668
Background And Objectives: A specific method is required for estimating glomerular filtration rate GFR in hospitalized patients. Our objective was to validate the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation...
8.
Fernandez-Fresnedo G, Segarra A, Gonzalez E, Alexandru S, Delgado R, Ramos N, et al.
Clin J Am Soc Nephrol
. 2009 Jul;
4(8):1317-23.
PMID: 19578004
Background And Objectives: Isolated case reports have shown a beneficial effect of rituximab on pediatric patients with primary FSGS, but there is no information about rituximab treatment of FSGS in...
9.
Tovar J, Buti M, Segarra A, Majo J, Esteban R
Int Urol Nephrol
. 2007 Nov;
40(2):539-41.
PMID: 17987400
This paper describes the case of a patient with HCV, without previous evidence of nephropathy, who following two well-tolerated cycles of treatment with interferon alone developed nephrotic syndrome after a...
10.
Ferrando J, Vidal J, Armengol M, Gil J, Manero J, Huguet P, et al.
World J Surg
. 2002 Mar;
26(4):409-15.
PMID: 11910471
The use of a new type of prosthesis, Bard Composix (BC), constructed of two layers of polypropylene mesh (PP) and one layer of expanded polytetrafluoroethylene (ePTFE), could provide a good...